Suzanne R Hayman

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc VEGF inhibition, hypertension, and renal toxicity
    Suzanne R Hayman
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Curr Oncol Rep 14:285-94. 2012
  2. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
  3. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
  4. pmc High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    Sumit Madan
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Blood 119:1117-22. 2012
  5. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
  6. doi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
  7. doi request reprint Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 89:302-5. 2014
  8. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
  9. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
  10. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011

Detail Information

Publications89

  1. pmc VEGF inhibition, hypertension, and renal toxicity
    Suzanne R Hayman
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Curr Oncol Rep 14:285-94. 2012
    ..These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life...
  2. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  3. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  4. pmc High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    Sumit Madan
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Blood 119:1117-22. 2012
    ..01). In multivariate analysis of baseline factors, only reduced-dose melphalan predicted shorter OS. HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ response is associated with improved survival...
  5. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  6. doi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  7. doi request reprint Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 89:302-5. 2014
    ..05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control...
  8. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  9. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  10. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  11. doi request reprint Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:2181-7. 2010
    ..001). The only predictor of survival was cardiac stage (p  < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival...
  12. pmc Trends and outcomes of modern staging of solitary plasmacytoma of bone
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:647-51. 2012
    ..The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up...
  13. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  14. pmc Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
    Martha Q Lacy
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 118:2970-5. 2011
    ..Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896...
  15. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  16. doi request reprint Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
    Shaji K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:614-7. 2008
    ..The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age...
  17. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  18. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  19. doi request reprint Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:205-11. 2008
    ..Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma...
  20. ncbi request reprint In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  21. pmc Outcomes of patients with POEMS syndrome treated initially with radiation
    Michael S Humeniuk
    Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 122:68-73. 2013
    ..The presence of 3 lesions compared with 1 or 2 did not increase risk for treatment failure. Among selected patients with POEMS syndrome, radiation produces durable, meaningful responses. ..
  22. ncbi request reprint Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy
    Taimur Sher
    Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida 32246, USA
    Clin Adv Hematol Oncol 10:644-51. 2012
    ..Newer agents such as bortezomib and lenalidomide have shown promising activity and are being evaluated as part of combination regimens in clinical trials...
  23. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
    ..We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896...
  24. doi request reprint Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  25. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
    ..The trial was registered at www.clinicaltrials.gov (NCT00564889)...
  26. doi request reprint Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 115:2348-53; quiz 2560. 2010
    ..5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy...
  27. pmc Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 30:989-95. 2012
    ..However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification...
  28. pmc Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
    Shirshendu Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 148:853-8. 2010
    ..Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome...
  29. doi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  30. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  31. doi request reprint Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency
    Stefan Cordes
    aDepartment of Internal Medicine bDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Blood Coagul Fibrinolysis 27:101-8. 2016
    ..54; P = 0.04) and proteinuria (ρ = -0.54; P = 0.04). Our findings support the decision to offer ASCT to factor X-deficient patients as both appropriate and efficacious...
  32. pmc Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin J Am Soc Nephrol 7:1964-8. 2012
    ....
  33. ncbi request reprint Relationship between depth of response and outcome in multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:4933-7. 2007
    ..We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS...
  34. doi request reprint The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome
    Anita D'Souza
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 118:4663-5. 2011
    ..Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response...
  35. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  36. pmc Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:1585-92. 2012
    ..It is not clear whether this paradigm holds true in the context of new therapies, such as immunomodulatory drugs (IMiDs)...
  37. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  38. pmc Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation
    Abhishek Singla
    Department of Internal Medicine, Creighton University Medical Center, Omaha, Nebraska, USA
    Biol Blood Marrow Transplant 19:1233-7. 2013
    ....
  39. pmc A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester MN, USA
    Haematologica 98:988-92. 2013
    ..In particular, discrimination of the renal response into complete and partial categories and modification of the serum creatinine requirement seem justified...
  40. doi request reprint Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization
    Ivana N M Micallef
    Division of Hematology Blood and Marrow Transplantation, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 19:87-93. 2013
    ....
  41. pmc A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  42. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  43. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  44. ncbi request reprint Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 2:440-4. 2007
    ..Achievement of renal response was associated with improved survival. These results suggest that early intervention with aggressive therapy is not only justified but recommended to achieve optimal response...
  45. ncbi request reprint Serum M-spike and transplant outcome in patients with multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:1035-40. 2007
    ..The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease...
  46. doi request reprint Immunoglobulin D amyloidosis: a distinct entity
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 119:44-8. 2012
    ..The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein...
  47. pmc Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 118:1763-5. 2011
    ..Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide...
  48. pmc Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 119:2100-5. 2012
    ..Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers...
  49. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  50. doi request reprint Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis
    Stefan Cordes
    Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 118:6105-9. 2012
    ..The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT)...
  51. doi request reprint Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation
    Jonathan S Bleeker
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 89:228-35. 2012
    ..Cardiac complications following hematopoietic stem cell transplantation (HSCT) are emerging as a significant concern given the increasing utilization of HSCT for a variety of hematologic malignancies...
  52. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  53. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  54. ncbi request reprint Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma
    Rajshekhar Chakraborty
    a Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 58:308-315. 2017
    ..In conclusion, pre-transplant BMPC <5% is an important prognostic marker of long-term survival after transplant and should be routinely incorporated into pre-transplant risk stratification...
  55. doi request reprint The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, MN, USA Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 31:1284-9. 2016
    ..This study examined the association between acute renal failure and mortality in immunoglobulin light chain (AL) amyloidosis during ASCT...
  56. doi request reprint Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 91:585-9. 2016
    ..Am. J. Hematol. 91:585-589, 2016. © 2016 Wiley Periodicals, Inc. ..
  57. pmc Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota
    Cancer 122:2197-205. 2016
    ..Autologous stem cell transplantation (SCT) is a common management strategy for select patients with immunoglobulin light-chain amyloidosis, but no trials have documented improved overall survival...
  58. doi request reprint Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation
    Yi L Hwa
    Division of Hematology, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 91:984-8. 2016
    ..Prospective studies will be required to sort out these and other questions. Am. J. Hematol. 91:984-988, 2016. © 2016 Wiley Periodicals, Inc. ..
  59. pmc Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type
    Eli Muchtar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Haematologica 101:1102-9. 2016
    ..Melphalan at first-line provided poorer outcomes for patients with significant immunoparesis, while bortezomib or immunomodulatory drugs were more likely to overcome the adverse prognosis associated with significant immunoparesis. ..
  60. doi request reprint Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, Minnesota
    JAMA Oncol . 2017
    ..Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system...
  61. pmc Smoldering multiple myeloma requiring treatment: time for a new definition?
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, MN
    Blood 122:4172-81. 2013
    ....
  62. ncbi request reprint Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 92:1415-8. 2007
    ..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival...
  63. doi request reprint Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis
    Maria V Irazabal
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:51-4. 2012
    ..While infectious etiology accounted for some of the AKI, most appeared to be associated with ES. After infection is ruled out, ES should be considered in the differential diagnosis when evaluating AKI in this population...
  64. doi request reprint Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 90:524-8. 2015
    ..The addition of sST2 - but not galectin-3 - to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death...
  65. doi request reprint Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, MN Electronic address
    Mayo Clin Proc 90:1054-81. 2015
    ..Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion. ..
  66. doi request reprint Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 89:1051-4. 2014
    ..Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis...
  67. doi request reprint Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Eur J Haematol 92:485-90. 2014
    ..In conclusion, our study indicates that patients with AL amyloidosis fare well post-transplant relapse/progression. Additionally, it provides a yardstick to design clinical trials to determine best treatment options. ..
  68. pmc Implications of continued response after autologous stem cell transplantation for multiple myeloma
    Wilson I Gonsalves
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 122:1746-9. 2013
    ..001), and overall survival (96 vs 57 months, P < .001). This phenomenon of a continued response maintained prognostic value in a multivariable analysis and should be considered when interpreting posttransplant responses. ..
  69. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  70. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:343-60. 2006
    ..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy...
  71. ncbi request reprint Transplantation for amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 19:136-41. 2007
    ..We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature...
  72. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  73. doi request reprint Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years
    Pankaj Malhotra
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1724-30. 2008
    ..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
  74. doi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
    ..Historically, patients with AL amyloidosis and overt congestive heart failure have had an ominous prognosis with median survival of approximately 6 months...
  75. doi request reprint Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Hilmi Ege
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 141:792-8. 2008
    ..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM...
  76. doi request reprint Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
    Sandra M S Herrmann
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN, USA
    Nephrol Dial Transplant 26:2032-6. 2011
    ..Kidney transplantation (KTx) has become more common but the long-term outcomes remain unknown and it is the objective of this study...
  77. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  78. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  79. pmc A novel report of cig-FISH and cytogenetics in POEMS syndrome
    Alan H Bryce
    Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 83:840-1. 2008
    ..Three patients had IgH translocation t(11;14)(q13;q32). No abnormalities were seen at 17p13(p53). The monosomy 13 is in line with other plasma cell disorders while the low prevalence of hyperdiploidy and abnormalities at 14q32 is unique...
  80. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  81. doi request reprint Cancer patients and their companion animals: results from a 309-patient survey on pet-related concerns and anxieties during chemotherapy
    Brenda R Larson
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Cancer Educ 25:396-400. 2010
    ..Healthcare providers at other medical centers should consider determining whether their patients have needs and anxieties related to caring for their pets and whether educational efforts should be put forth to focus on such issues...
  82. ncbi request reprint Treatment of immunoglobulin light chain (primary or AL) amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 25:620-6. 2011
    ..The role of the recently introduced novel agents in management of amyloidosis is also reviewed...
  83. doi request reprint Transplantation for IgM amyloidosis and IgM myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:77-9. 2009
    ..IgM patients are older, and the amyloidosis cohort has a higher incidence of neuropathy and lower incidence of cardiac involvement by echocardiography and troponin T level...
  84. doi request reprint IgM amyloidosis: clinical features in therapeutic outcomes
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma Leuk 11:146-8. 2011
    ..IgM patients are older, have a higher prevalence of neuropathy, a lower incidence of cardiac involvement (lower troponin T and NT-proBNP), and a much lower level of the involved immunoglobulin free light chain...
  85. ncbi request reprint Amyloidosis: diagnosis and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Lymphoma Myeloma 6:208-19. 2005
    ..New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide...
  86. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  87. doi request reprint Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis
    Ghormallah B Al-Zahrani
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Am Soc Echocardiogr 22:290-8. 2009
    ....
  88. ncbi request reprint Hypertension in pregnancy: an emerging risk factor for cardiovascular disease
    Vesna D Garovic
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street South West, Rochester, MN 55905, USA
    Nat Clin Pract Nephrol 3:613-22. 2007
    ..Women at high risk must be monitored closely for conventional risk factors that are common to both CVD and hypertensive disorders of pregnancy and treated according to current evidence-based national guidelines...
  89. ncbi request reprint Incidence and prognosis of acute heart failure in the thrombotic microangiopathies
    Apoor S Gami
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Med 118:544-7. 2005